Literature DB >> 11678789

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

M G Scordo1, E Aklillu, U Yasar, M L Dahl, E Spina, M Ingelman-Sundberg.   

Abstract

AIMS: CYP2C9 is a major enzyme in human drug metabolism and the polymorphism observed in the corresponding gene may affect the therapeutic outcome during treatment with several drugs. The distribution of variant CYP2C9 alleles was therefore investigated in an Italian and an Ethiopian population.
METHODS: Allele-specific PCR analysis was carried out in order to determine the frequencies of the two most common variant alleles, CYP2C9*2 and CYP2C9*3 in genomic DNA isolated from 157 Italians and 150 Ethiopians.
RESULTS: The frequencies of CYP2C9*1 (80%), CYP2C9*2 (11%) and CYP2C9*3 (9%) found in the Italian population were similar to other Caucasian groups. However in the Ethiopian population CYP2C9*1, CYP2C9*2 and CYP2C9*3 were present at a frequency of 94, 4 and 2% respectively. The 95% confidence intervals in CYP2C9*1, CYP2C9*2 and CYP2C9*3 between Italians and Ethiopians were 0.098, 0.176, 0.040, 0.098 and 0.040, 0.098, respectively.
CONCLUSIONS: Our results indicate that the Ethiopian population has a unique relative distribution of the CYP2C9 alleles, which is not similar to any other ethnic group hitherto described.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11678789      PMCID: PMC2014581          DOI: 10.1046/j.0306-5251.2001.01460.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

Review 1.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment.

Authors:  M Ingelman-Sundberg; M Oscarson; R A McLellan
Journal:  Trends Pharmacol Sci       Date:  1999-08       Impact factor: 14.819

2.  Genetic analysis of CYP2C9 polymorphism in a Japanese population.

Authors:  K Nasu; T Kubota; T Ishizaki
Journal:  Pharmacogenetics       Date:  1997-10

3.  A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity.

Authors:  C Masimirembwa; I Persson; L Bertilsson; J Hasler; M Ingelman-Sundberg
Journal:  Br J Clin Pharmacol       Date:  1996-12       Impact factor: 4.335

4.  Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.

Authors:  E Aklillu; I Persson; L Bertilsson; I Johansson; F Rodrigues; M Ingelman-Sundberg
Journal:  J Pharmacol Exp Ther       Date:  1996-07       Impact factor: 4.030

5.  Genetic analysis of the human cytochrome P450 CYP2C9 locus.

Authors:  M J Stubbins; L W Harries; G Smith; M H Tarbit; C R Wolf
Journal:  Pharmacogenetics       Date:  1996-10

6.  Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.

Authors:  A S Aynacioglu; J Brockmöller; S Bauer; C Sachse; P Güzelbey; Z Ongen; M Nacak; I Roots
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

7.  Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

Authors:  U Yasar; E Eliasson; M L Dahl; I Johansson; M Ingelman-Sundberg; F Sjöqvist
Journal:  Biochem Biophys Res Commun       Date:  1999-01-27       Impact factor: 3.575

8.  Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.

Authors:  M Kimura; I Ieiri; K Mamiya; A Urae; S Higuchi
Journal:  Ther Drug Monit       Date:  1998-06       Impact factor: 3.681

9.  Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.

Authors:  S L Wang; J Huang; M D Lai; J J Tsai
Journal:  Pharmacogenetics       Date:  1995-02

Review 10.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Authors:  J O Miners; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

View more
  48 in total

1.  Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population.

Authors:  Maria Burian; Sabine Grösch; Irmgard Tegeder; Gerd Geisslinger
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

2.  Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Authors:  Al-Motassem Yousef; Nailya R Bulatova; William Newman; Nancy Hakooz; Said Ismail; Hisham Qusa; Farah Zahran; Nidaa Anwar Ababneh; Farah Hasan; Imad Zaloom; Ghada Khayat; Rawan Al-Zmili; Randa Naffa; Ola Al-Diab
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

3.  A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Authors:  Su-Jun Lee; Yin Jin Jang; Eun-Young Cha; Ho-Sook Kim; Sang Seop Lee; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

Review 4.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  CYP2C8 polymorphism frequencies among malaria patients in Zanzibar.

Authors:  I Cavaco; J Strömberg-Nörklit; A Kaneko; M I Msellem; M Dahoma; V L Ribeiro; A Bjorkman; J P Gil
Journal:  Eur J Clin Pharmacol       Date:  2005-01-27       Impact factor: 2.953

6.  The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.

Authors:  Ya-Huei Liou; Chien-Ting Lin; Ying-Jye Wu; Lawrence Shih-Hsin Wu
Journal:  J Hum Genet       Date:  2006-08-19       Impact factor: 3.172

Review 7.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 8.  Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Authors:  Rashmi R Shah
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 9.  Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.

Authors:  Christine M Walko; Howard McLeod
Journal:  Nat Clin Pract Oncol       Date:  2009-01-27

10.  CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.

Authors:  Pedro Dorado; Roland Berecz; Maria-Jesús Norberto; Umit Yasar; Marja-Liisa Dahl; Adrián LLerena
Journal:  Eur J Clin Pharmacol       Date:  2003-05-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.